About Biogen Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.biogen.com/
Frequently Asked Questions
What is the 52-week range for BIIB?
The 52-week high is $230.49 and the 52-week low is $138.
What is the P/E ratio for BIIB?
The Price to Earnings (P/E) ratio is 39.24.
What is the dividend yield for BIIB?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 4.51%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 8.32%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.41.
Analyst Recommendation Trends
Wall Street analyst consensus for BIIB over the last few months:
Latest BIIB News
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively)Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks -- consistent with results seen in participants who started
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.
1 Profitable Stock Worth Investigating and 2 We Ignore
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
HLS Therapeutics Announces Board of Directors Changes
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the "Board"), effective today. The appointments follow the departures of Dr. Kyle Dempsey and Christine Elliott. Following these changes, the Board comprises eight directors, six of whom are independent.
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data
Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, while Biogen also published Phase 3 VALIANT adolescent subgroup data showing EMPAVELI improved proteinuria and stabilized kidney function in rare complement-mediated kidney disorders. Together, these updates highlight Biogen’s push to make complex therapies more accessible in real-world settings, potentially broadening treatment reach in both...
Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets
Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO) stock dropped sharply on Monday after the company laid out new long-term goals that failed to convince investors it can hold its ground against fast-growing rivals in the weight loss drug market.
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva
Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness.
Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?
Biogen (BIIB) is back in focus after publishing adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, a catalyst that gives investors fresh clinical context around the stock. For context, Biogen’s recent clinical and product news has landed against a backdrop of stronger trading action, with a 1-day share price return of 2.87% on the latest close at US$225.36 and a 90-day share price return of 12.91%. Investors are weighing kidney and Alzheimer’s updates...
Novo defends diversification push as CEO eyes deals beyond obesity
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors
Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...
Novo shares slide as drugmaker lays out post-Wegovy growth strategy
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT studyPublication follows a recent FDA label update to expand EMPAVELI’s indication to include reducing the loss of kidney function in patients 12 years and older, in addition to reducing proteinuria CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today ann
Biogen Announces Publication Of Phase 3 VALIANT Adolescent Subgroup Data In CJASN Demonstrating 75% Proteinuria Reduction For EMPAVELI In Rare Kidney Diseases
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT
Biogen: Growth Is Back, But It Came At A Price
Biogen pivots to Leqembi/Skyclarys and the Apellis deal to revive growth, but upside looks limited.
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.
Is Biogen Stock Outperforming the S&P 500?
Biogen has outpaced the broader S&P 500 Index over the past year, and analysts remain reasonably upbeat about the stock’s prospects.
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive DiseaseTOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody “LEQEMBI®” (brand name, generic name: lecanemab) has been approved in Japan as a new route of administration. LEQEMBI Pen is an autoinj
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NYSE:ABBV)’s ratings from Peer Perform, with Wolfe assigning them similar $300 price targets. The firm’s logic in each case was based on a comparable set of factors: pipelines that the market appears to […]
Hummingbird Bioscience Appoints Dr. James Garner as President
Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience (“Hummingbird”), a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced the appointment of Dr. James Garner as President. Dr. Garner will join Hummingbird Bioscience’s leadership team and work alongside
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quart
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Biogen Inc. (BIIB) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 9:15 AM EDTCompany ParticipantsChristopher Viehbacher -...
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology
Biogen (NASDAQ:BIIB) executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth. Speaking at a Wells Fargo conference, Chief Financial Officer Robin Kramer said B
Thursday's session: top gainers and losers in the S&P500 index
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.
HSBC Maintains Reduce on Biogen, Raises Price Target to $175
HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.
Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Biogen Inc. (BIIB) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 9:30 AM EDTCompany ParticipantsRobin Kramer - Executive VP & CFOAdam...
Biogen CEO: We are at that inflection point where we are on a path to sustainable revenue growth
Biogen CEO Christopher Viehbacher joins 'Squawk on the Street' to discuss their upcoming product pipeline, developments in Alzheimer treatment and medication and more.
Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit
FAIRFIELD, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- With just two days remaining before registration closes for HMG Strategy's 18th Annual Boston C-Level Technology Leadership Summit, qualified technology executives are encouraged to secure their seats now while limited seating remains available. The September 10 summit at The Harvard Club of Boston will bring together CIOs, CISOs, CTOs, Chief Digital Officers, Chief AI Officers and other senior technology leaders to discuss AI governance, Agen
Lilly Builds Neuroscience into a New Long-Term Growth Driver
Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...
Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced presentations
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass., September 03, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. Drave
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...
Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment
Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative DiseaseTOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (Chinese trademark: 乐意保®
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-01 | Parini Michael | +7,405 | - | - |
| 2026-08-04 | Minor Lloyd | -593 | $200.96 | $119,169 |
| 2026-08-03 | Minor Lloyd | -593 | $203.34 | $120,581 |
| 2026-06-09 | Minor Lloyd | +1,505 | - | - |
| 2026-06-09 | Pangalos Menelas N | -2,370 | - | - |
| 2026-06-09 | Pangalos Menelas N | +1,505 | - | - |
| 2026-06-09 | Pangalos Menelas N | +2,370 | - | - |
| 2026-06-09 | LANGER SUSAN | +1,505 | - | - |
| 2026-06-09 | Patolawala Monish D | +1,505 | - | - |
| 2026-06-09 | Mantas Jesus B | +1,505 | - | - |
| 2026-06-09 | Freire Maria C | +2,005 | - | - |
| 2026-06-09 | Rowinsky Eric K | +1,505 | - | - |
| 2026-06-09 | HAWKINS WILLIAM A | +1,505 | - | - |
| 2026-06-09 | SHERWIN STEPHEN A | +1,505 | - | - |
| 2026-05-01 | Keeney Adam | -939 | - | - |
| 2026-05-01 | Keeney Adam | -455 | $187.06 | $85,112 |
| 2026-05-01 | Keeney Adam | +939 | - | - |
| 2026-04-01 | Godbout Sean | -181 | - | - |
| 2026-04-01 | Godbout Sean | -54 | $183.78 | $9,924 |
| 2026-04-01 | Godbout Sean | +181 | - | - |
| 2026-02-13 | Godbout Sean | +1,800 | - | - |
| 2026-02-13 | Grogan Jane | +8,450 | - | - |
| 2026-02-13 | Keeney Adam | +8,025 | - | - |
| 2026-02-13 | Murphy Nicole | +10,560 | - | - |
| 2026-02-13 | Izzar Rachid | +7,390 | - | - |
| 2026-02-13 | Viehbacher Christopher | +38,015 | - | - |
| 2026-02-13 | Singhal Priya | +10,560 | - | - |
| 2026-02-13 | Kramer Robin | +8,450 | - | - |
| 2026-02-13 | Gregory Ginger | +8,025 | - | - |
| 2026-02-13 | ALEXANDER SUSAN H | +8,450 | - | - |
| 2026-02-12 | Murphy Nicole | +3 | $195.035 | $585 |
| 2026-02-09 | Singhal Priya | -2,660 | $199.83 | $531,548 |
| 2026-02-06 | Godbout Sean | -517 | - | - |
| 2026-02-06 | Godbout Sean | -305 | - | - |
| 2026-02-06 | Godbout Sean | -257 | - | - |
| 2026-02-06 | Godbout Sean | -180 | $201.18 | $36,212 |
| 2026-02-06 | Godbout Sean | +517 | - | - |
| 2026-02-06 | Godbout Sean | -103 | $201.18 | $20,722 |
| 2026-02-06 | Godbout Sean | +305 | - | - |
| 2026-02-06 | Godbout Sean | -76 | $201.18 | $15,290 |
| 2026-02-06 | Godbout Sean | +257 | - | - |
| 2026-02-06 | Grogan Jane | -1,873 | - | - |
| 2026-02-06 | Grogan Jane | -1,385 | - | - |
| 2026-02-06 | Grogan Jane | -584 | $201.18 | $117,489 |
| 2026-02-06 | Grogan Jane | +1,873 | - | - |
| 2026-02-06 | Grogan Jane | -407 | $201.18 | $81,880 |
| 2026-02-06 | Grogan Jane | +1,385 | - | - |
| 2026-02-06 | Keeney Adam | -3,278 | - | - |
| 2026-02-06 | Keeney Adam | -1,802 | - | - |
| 2026-02-06 | Keeney Adam | -994 | $201.18 | $199,973 |
| 2026-02-06 | Keeney Adam | +3,278 | - | - |
| 2026-02-06 | Keeney Adam | -589 | $201.18 | $118,495 |
| 2026-02-06 | Keeney Adam | +1,802 | - | - |
| 2026-02-06 | Murphy Nicole | -4,683 | - | - |
| 2026-02-06 | Murphy Nicole | -1,940 | - | - |
| 2026-02-06 | Murphy Nicole | -2,102 | - | - |
| 2026-02-06 | Murphy Nicole | -1,408 | $201.18 | $283,261 |
| 2026-02-06 | Murphy Nicole | +4,683 | - | - |
| 2026-02-06 | Murphy Nicole | -914 | $201.18 | $183,879 |
| 2026-02-06 | Murphy Nicole | +1,940 | - | - |
| 2026-02-06 | Murphy Nicole | -1,017 | $201.18 | $204,600 |
| 2026-02-06 | Murphy Nicole | +2,102 | - | - |
| 2026-02-06 | Izzar Rachid | -3,043 | - | - |
| 2026-02-06 | Izzar Rachid | -1,802 | - | - |
| 2026-02-06 | Izzar Rachid | -2,044 | - | - |
| 2026-02-06 | Izzar Rachid | -775 | $201.18 | $155,915 |
| 2026-02-06 | Izzar Rachid | +3,043 | - | - |
| 2026-02-06 | Izzar Rachid | -458 | $201.18 | $92,140 |
| 2026-02-06 | Izzar Rachid | +1,802 | - | - |
| 2026-02-06 | Izzar Rachid | -805 | $201.18 | $161,950 |
| 2026-02-06 | Izzar Rachid | +2,044 | - | - |
| 2026-02-06 | Viehbacher Christopher | -15,453 | - | - |
| 2026-02-06 | Viehbacher Christopher | -9,008 | - | - |
| 2026-02-06 | Viehbacher Christopher | -6,624 | $201.18 | $1,332,616 |
| 2026-02-06 | Viehbacher Christopher | +15,453 | - | - |
| 2026-02-06 | Viehbacher Christopher | -4,356 | $201.18 | $876,340 |
| 2026-02-06 | Viehbacher Christopher | +9,008 | - | - |
| 2026-02-06 | Singhal Priya | -4,683 | - | - |
| 2026-02-06 | Singhal Priya | -2,217 | - | - |
| 2026-02-06 | Singhal Priya | -1,412 | $201.18 | $284,066 |
| 2026-02-06 | Singhal Priya | +4,683 | - | - |
| 2026-02-06 | Singhal Priya | -1,056 | $201.18 | $212,446 |
| 2026-02-06 | Singhal Priya | +2,217 | - | - |
| 2026-02-06 | Kramer Robin | -3,511 | - | - |
| 2026-02-06 | Kramer Robin | -703 | - | - |
| 2026-02-06 | Kramer Robin | -789 | - | - |
| 2026-02-06 | Kramer Robin | -1,063 | $201.18 | $213,854 |
| 2026-02-06 | Kramer Robin | +3,511 | - | - |
| 2026-02-06 | Kramer Robin | -207 | $201.18 | $41,644 |
| 2026-02-06 | Kramer Robin | +703 | - | - |
| 2026-02-06 | Kramer Robin | -273 | $201.18 | $54,922 |
| 2026-02-06 | Kramer Robin | +789 | - | - |
| 2026-02-06 | Gregory Ginger | -3,746 | - | - |
| 2026-02-06 | Gregory Ginger | -1,802 | - | - |
| 2026-02-06 | Gregory Ginger | -1,635 | - | - |
| 2026-02-06 | Gregory Ginger | -1,132 | $201.18 | $227,736 |
| 2026-02-06 | Gregory Ginger | +3,746 | - | - |
| 2026-02-06 | Gregory Ginger | -666 | $201.18 | $133,986 |
| 2026-02-06 | Gregory Ginger | +1,802 | - | - |
| 2026-02-06 | Gregory Ginger | -791 | $201.18 | $159,133 |
| 2026-02-06 | Gregory Ginger | +1,635 | - | - |
| 2026-02-06 | ALEXANDER SUSAN H | -4,916 | - | - |
| 2026-02-06 | ALEXANDER SUSAN H | -1,940 | - | - |
| 2026-02-06 | ALEXANDER SUSAN H | -2,190 | - | - |
| 2026-02-06 | ALEXANDER SUSAN H | -1,514 | $201.18 | $304,587 |
| 2026-02-06 | ALEXANDER SUSAN H | +4,916 | - | - |
| 2026-02-06 | ALEXANDER SUSAN H | -931 | $201.18 | $187,299 |
| 2026-02-06 | ALEXANDER SUSAN H | +1,940 | - | - |
| 2026-02-06 | ALEXANDER SUSAN H | -1,059 | $201.18 | $213,050 |
| 2026-02-06 | ALEXANDER SUSAN H | +2,190 | - | - |
| 2026-02-02 | Singhal Priya | -748 | $179.3 | $134,116 |
| 2026-01-30 | Singhal Priya | -1,829 | - | - |
| 2026-01-30 | Singhal Priya | -582 | $179.89 | $104,696 |
| 2026-01-30 | Singhal Priya | +1,829 | - | - |
| 2025-12-01 | Viehbacher Christopher | -7,040 | - | - |
| 2025-12-01 | Viehbacher Christopher | -3,404 | $177.78 | $605,163 |
| 2025-12-01 | Viehbacher Christopher | +7,040 | - | - |
| 2025-10-31 | Grogan Jane | -695 | - | - |
| 2025-10-31 | Grogan Jane | -337 | $154.27 | $51,989 |
| 2025-10-31 | Grogan Jane | +695 | - | - |